Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the major impact that regorafenib and sorafenib will have for the treatment of liver cancer.
Jordi Bruix, MD
Advertisement
Articles by Jordi Bruix, MD
Advertisement
Latest Updated Articles
Impact of Regorafenib and Sorafenib in the Treatment of Liver CancerPublished: July 6th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
